"Screening For Drugs That

Enzyme"

Affect TNF Receptor Releasing

	CERTIFICATE OF MAILING	,	
I hereby certify that this correspondence is being deposited Commissioner for Patents, Washington, D.C. 20231.	with the United States Postal Service as	first class mail in an envelope	addressed to: Assistant
Typed or Printed Name Steven F. Goldstein			
Signature Signature	la Da	Date March 21, 200	_ ~
	•33400		- E - E
AMENDMENT UNDER 37 C.F.R. §1.111	Attorney Docket Confirmation No.	IRVN-007CON2 1505	두 : [25]
	First Named Inventor	Tetsuya Gatanag	a ဟ (C
	Application Number	09/752,639	, 1
Address to:	Filing Date	December 29, 2000	
Box	Group Art Unit	1646	
Assistant Commissioner for Patents	Examiner Name	Joseph F. Murph	y 🗲 👱

Dear Sir,

Washington, D.C. 20231

This paper is responsive to the most recent Office Action on the merits, dated September 26, 2002 (Paper No. 10), for which a response is due December 26, 2002. Accompanying this paper is a Petition for a Three Month Extension of time, along with authorization to charge the Deposit Account for the requisite fee. This sets the deadline to March 26, 2003. Accordingly, this paper is timely filed.

Title

Applicant has given careful consideration to the analysis in the Office Action. Please enter the following amendments and remarks.

AMENDMENTS

CLAIM AMENDMENTS

- 33. (Currently amended) A method of screening substances for an ability to affect TRRE TNF receptor releasing activity, comprising:
 - a) incubating TNF receptor or cells expressing TNF receptor with the substance and with a <u>an isolated</u> polypeptide that causes TNF receptor to be cleaved in the absence of the substance;
 - b) measuring any TNF receptor cleaved; and